US Edition
Naifencon(R) and EVER001 Work Together to Promote Kidney Disease Treatment Into a New Stage of Precision Management – EastMud
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Kidney Disease Treatment into a New Era of Precision Management HONG KONG, Jun 12, 2025 - (ACN Newswire) - At the 62nd Congress of the European Renal Association (ERA 2025), Everest Medicines presented new results findings on both NEFECON® (budesonide delayed release capsules), the world's first and only approved therapy that directly targets the underlying cause of IgA nephropathy (IgAN), and EVER001, a next-generation covalent reversible BTK i…
HONG KONG, June 12, 2025 – (Asia Pacific Business News via SeaPRwire.com) – At the 62nd European Renal Association (ERA 2025) Congress, Everest Medicines (HKEX: 1952.
HONG KONG, June 12, 2025 – (Asia Pacific Business News via SeaPRwire.com) – At the 62nd European Renal Association (ERA 2025) Congress, Everest Medicines (HKEX: 1952.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
